Pembrolizumab (KEYTRUDA® ) clinical trials
6 indexed studies · 4 currently recruiting
- RecruitingPHASE2, PHASE3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
This study is looking at a new treatment called EIK1001 when given with standard treatment (Pembrolizumab) for advanced melanoma. It aims to see if this combination is safe and effective compared to Pembrolizumab alone for people whose melanoma has spread.
For: Advanced MelanomaUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
For: Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
This study is testing a new drug, BI-1607, combined with two existing cancer drugs, pembrolizumab and ipilimumab, for advanced melanoma. Researchers want to see if this new combination is safe, effective, and helps patients whose cancer hasn't responded to other treatments.
For: Melanoma Metastatic · Melanoma of Skin · Melanoma BRAF V600E/K MutatedGermany · Spain · United Kingdom - Active not recruitingPHASE3
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
This study is looking at a new treatment called efti, combined with standard care, for advanced lung cancer. It compares how well this combination works against the standard care alone to see if it helps people live longer and stops cancer from growing for longer. Participants will receive treatment for up to two years.
For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - RecruitingPHASE2
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study is looking at a new way to treat certain breast cancers before surgery. It combines a special type of radiation with a medicine called pembrolizumab, followed by standard chemotherapy, to see if it can make treatments more effective.
For: Breast Cancer · Breast Cancer Stage II · Breast Cancer Stage IIICanada - RecruitingPHASE3
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
This study looks at new treatments, ivonescimab and ligufalimab, for head and neck cancer that has come back or spread, and compares them to a standard drug, pembrolizumab. It aims to see if the new treatments can help people live longer.
For: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)France